Instruction for use: Antihemophillic factor human-M (AHF-M)

Dosage form: Lyophilizate for the preparation of a solution for infusions

Active substance: Coagulation factor VIII

ATX

B02BD02 Coagulation factor VIII

Pharmacological group:

Coagulants (including factors of blood coagulation), hemostatics

Composition and release form

1 bottle with a sterile, lyophilized powder for the preparation of the injection solution contains a clotting factor VIII 200-300, 400-600 or 800-1200 IU, complete with a solvent - water for injection in 10 ml vials, a double-sided needle and a filter needle.

Dosing and Administration

• IV, at a rate of 2-3 ml / min. The dosage regimen is set individually under the control of the coagulation factor VIII activity. With joint, muscle and tissue bleedings, the level of activity of factor VIII is increased to 10-20% (duration of treatment is not less than 2-3 days); Removal of the tooth or small operations - not less than 30% (5 days), gastrointestinal bleeding - at least 30-50% (10-14 days); Extensive surgical interventions or intracranial hemorrhages - no less than 60% (2-3 weeks). The initial dose (IU) is calculated as the product of the desired increase in factor VIII (%) content per body weight (kg), the maintenance dose being half the initial dose. For prolonged prevention of bleeding in severe haemophilia A - 12-25 IU / kg every 2-3 days.

Storage conditions of the drug Antihemophillic factor human-M (AHF-M)

At a temperature of 2-8 ° C.

Keep out of the reach of children.

Shelf life of Antihemophillic factor human-M (AHF-M)

2 years.

Do not use after the expiry date printed on the package.